The associate professor of neurology at the Perelman School of Medicine at the University of Pennsylvania discussed pivotal data on zilganersen, highlighting its efficacy, safety, and potential as the first disease-modifying therapy for Alexander disease.
The director of the Center for Neurological Restoration at Cleveland Clinic discussed long-term TEMPO-4 data evaluating tavapadon’s impact on symptom control and levodopa utilization in Parkinson disease.
New long-term and post hoc data presented at the 2026 AAN Annual Meeting highlighted durable efficacy, safety, and patient-centered outcomes with nipocalimab in antibody-positive generalized myasthenia gravis.
The founder and president of the Indian Federation of Neurorehabilitation highlighted emerging technologies and evolving therapeutic strategies shaping the future of neurorehabilitation. [WATCH TIME: 5 minutes]
Jaime Ramos, PhD, Assistant Professor of Psychiatry and Neurology at NYU Grossman School of Medicine, discussed the role of neutrophil-to-lymphocyte ratio as a scalable inflammatory marker associated with future dementia risk.
CHMP has recommended tolebrutinib for nonrelapsing SPMS following phase 3 data showing reduced disability progression, supporting its role in targeting CNS-driven inflammation.
A duo of Baptist Health experts discussed emerging evidence suggesting that hormonal factors, sex-based clinical differences, and social roles contribute to distinct experiences for women with Parkinson disease.
The deputy director at Association of Movement Disorder Advanced Practice Providers (AMDAPP) recapped key themes in movement disorders presented at the 2026 AMDAPP conference. [WATCH TIME: 5 minutes]
Phase 3 data presented at AAN 2026 show that IVIG improves response rates in patients with autoimmune encephalitis refractory to steroids, supporting its role as a second-line immunotherapy option.
Here's some of what is coming soon to NeurologyLive® this week.
New pharmacokinetic data presented at AAN 2026 show that adolescents with focal epilepsy achieve cenobamate exposures comparable to adults, supporting simplified fixed-dose strategies and informing future pediatric development.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the MOGAD pipeline!
The assistant professor in the Department of Chemistry and Biochemistry at University of Nevada, Las Vegas reflected on receiving the first MDA Research Momentum Award at the 2026 MDA Conference. [WATCH TIME: 2 minutes]
Neurology News Network for the week ending April 25th, 2026. [WATCH TIME: 5 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 24, 2026.
A recent study suggested that probiotic regimens and biomarker-guided strategies may be a promising signal for reducing excessive daytime sleepiness in patients with PD and CKD.
Mitzi Joi Williams, MD, and Carol Coleman break down insurance basics, prior authorizations, and practical strategies to help patients navigate cost and access challenges at the start of the year.
A national survey presented at AAN 2026 revealed significant gaps between patients with epilepsy and clinicians in seizure expectations, treatment decisions, and communication around risks like SUDEP.
The neurologist at the University of Oklahoma Medical Center highlighted early diagnosis, prevention of secondary injury, and multimodal monitoring as key to improving patient outcomes in TBI. [WATCH TIME: 5 minutes]
FDA issues complete response letter for GTx-104 in aneurysmal subarachnoid hemorrhage, citing manufacturing and nonclinical concerns despite positive phase 3 efficacy and safety data.
At AAN 2026, an associate professor of neurology at University of Washington discussed how delays in antiamyloid treatment initiation for early Alzheimer disease may be driven by real-world factors. [WATCH TIME: 5 minutes]
In the phase 3 NIMBLE trial, Cemdisiran met primary and secondary endpoints, demonstrating rapid and sustained improvements in MG-ADL and QMG scores with once-every-12-week dosing in AChR-positive generalized myasthenia gravis.
Edith Graham, MD, assistant professor of neurology at Northwestern Feinberg School of Medicine, discussed diagnostic challenges and induction therapy outcomes in primary CNS vasculitis.
A phase 1b/2 trial presented at AAN 2026 showed HS-10506, a selective OX2R antagonist, significantly improved sleep latency and overall sleep outcomes in adults with insomnia.
A medical student at at Santa Casa de São Paulo School of Medical Sciences discussed the findings from a systematic review suggest potential biomarker-level benefits of estradiol-based hormone therapy in Alzheimer disease, but cautions that heterogeneous data limit firm conclusions. [WATCH TIME: 3 minutes]
New findings from a post hoc analysis of 2 phase 3 trials, presented at AAN 2026, reported that a majority of participants with advanced Parkinson disease had no troublesome dyskinesia at follow-up.
In the global phase 3 PREVAIL trial, gefurulimab met primary and secondary endpoints in adults with acetylcholine receptor antibody–positive generalized myasthenia gravis, potentially offering a more convenient alternative to intravenous therapies.
The president at Cala Health discussed the clinical role, evidence base, and future potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.
New findings presented at AAN 2025 showed that treatment with satralizumab was associated with a reduction in annualized relapse rate compared with placebo over 48 weeks in patients with MOGAD.
Data show ofatumumab maintains a steady safety profile in relapsing MS, with low serious infections, stable labs, and durable biomarker improvements.
